| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/07/2013 | US8435554 Compositons for nasal administration of pharmaceuticals |
| 05/07/2013 | US8435553 Elastin stabilization of connective tissue |
| 05/07/2013 | US8435552 Collagen/hydroxyapatite composite scaffold, and process for the production thereof |
| 05/07/2013 | US8435545 Capsule having broad color spectrum |
| 05/07/2013 | US8435544 Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors |
| 05/07/2013 | US8435520 Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
| 05/07/2013 | US8435504 Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
| 05/07/2013 | US8435503 Ophthalmic and ophthalmological use of a complex nutritive base in aqueous medium |
| 05/07/2013 | US8435499 Toothpowder composition containing wheat flour and bamboo salt |
| 05/07/2013 | US8435498 Penetrating pharmaceutical foam |
| 05/07/2013 | US8435497 Formoterol of and ciclesonide combination |
| 05/07/2013 | US8435496 Nanoparticle clusters and methods for forming same |
| 05/07/2013 | US8435451 Portable incense burner and storage device |
| 05/07/2013 | US8435225 Embolization protection system for vascular procedures |
| 05/07/2013 | US8435219 Self-destructing transdermal therapeutic system having improved functionality and efficacy |
| 05/07/2013 | DE202006021172U1 Transdermales therapeutisches System zur Verabreichung von Rivastigmin Transdermal therapeutic system for administering Rivastigmine |
| 05/07/2013 | CA2746516C Non-polar photosensitizer formulations for photodynamic therapy |
| 05/07/2013 | CA2681712C Tamibarotene capsule preparation |
| 05/07/2013 | CA2621015C New use for a composition comprising chloroprocaine hcl, a new composition comprising chloroprocaine hcl and a method for its manufacture |
| 05/07/2013 | CA2615121C Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion |
| 05/07/2013 | CA2564197C Activatable particles, preparations and uses |
| 05/07/2013 | CA2558029C Ion binding polymers and uses thereof |
| 05/07/2013 | CA2531566C Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
| 05/07/2013 | CA2530645C Dosage form |
| 05/07/2013 | CA2520968C Charged initiator polymers and methods of use |
| 05/02/2013 | WO2013063527A1 Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and t2d |
| 05/02/2013 | WO2013063510A1 Protein formulations containing amino acids |
| 05/02/2013 | WO2013063279A1 A high-loading nanoparticle-based formulation for water-insoluble steroids |
| 05/02/2013 | WO2013063271A1 Artemisinin and berberine compositions and methods of making |
| 05/02/2013 | WO2013063214A1 Novel compounds that are erk inhibitors |
| 05/02/2013 | WO2013063160A1 Methods and compositions for treating pain |
| 05/02/2013 | WO2013063125A1 Implantable drug delivery compositions and methods of treatment thereof |
| 05/02/2013 | WO2013063082A1 Implantable rasagiline compositions and methods of treatment thereof |
| 05/02/2013 | WO2013063079A1 Implantable tizanidine compositions and methods of treatment thereof |
| 05/02/2013 | WO2013063078A1 Anti-flush compositions |
| 05/02/2013 | WO2013063067A1 Enriched injectable emulsion containing selected fatty acid triglycerides |
| 05/02/2013 | WO2013063004A1 Device and method for sustained release of therapeutic agent |
| 05/02/2013 | WO2013062902A2 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with atorvastatin |
| 05/02/2013 | WO2013062570A1 Apparatus and method for producing controlled dosage of bioactive agent |
| 05/02/2013 | WO2013062498A1 Solid oral formulations comprising ebastine |
| 05/02/2013 | WO2013062497A1 Liquid pharmaceutical formulations |
| 05/02/2013 | WO2013062445A1 Pharmaceutical composition and kit for treating bacterial infections |
| 05/02/2013 | WO2013062441A1 Pharmaceutical combination of atorvastatin and nicergoline for the prophylaxis or treatment of disorders of the cerebral circulation |
| 05/02/2013 | WO2013062425A1 Ionophore antibiotic veterinary composition and method of manufacture |
| 05/02/2013 | WO2013062424A1 Method and composition for the treatment of pain and/or inflammation |
| 05/02/2013 | WO2013062202A1 Mri contrast agent coated with amphoteric ion |
| 05/02/2013 | WO2013062168A1 Composition containing chlorella extract for the prevention or treatment of liver disorders |
| 05/02/2013 | WO2013062073A1 Orally disintegrating tablet containing low-dose ramosetron |
| 05/02/2013 | WO2013062050A1 Aqueous gemcitabine solution preparation |
| 05/02/2013 | WO2013061969A1 Oxybutynin-containing transdermal absorption preparation |
| 05/02/2013 | WO2013061588A1 Transdermally absorbed preparation |
| 05/02/2013 | WO2013061350A1 Improved cross-linking composition delivered by iontophoresis, useful for the treatment of keratoconus |
| 05/02/2013 | WO2013061338A1 Pharmaceutical compositions of silodosin |
| 05/02/2013 | WO2013061269A1 Combinations of loteprednol and olopatadine for the treatment of ocular allergies |
| 05/02/2013 | WO2013061052A1 Novel dosage form |
| 05/02/2013 | WO2013060913A1 Micro-, submicro- and nano-structures containing amaranth protein |
| 05/02/2013 | WO2013060343A1 Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof |
| 05/02/2013 | WO2013060304A1 Solid dispersion of paclitaxel or homologue thereof and preparation method therefor |
| 05/02/2013 | WO2013060303A1 Polypeptides inhibiting neovascularization and uses thereof |
| 05/02/2013 | WO2013060258A1 Clavatine a-c, preparation method thereof and pharmaceutical composition and use thereof |
| 05/02/2013 | WO2013060179A1 Acyltetrahydro-β-carboline compounds as well as derivatives, applications and preparation methods thereof |
| 05/02/2013 | WO2013059984A1 Derivative of methacryloyl-benzimidazol-one (thione) and use thereof as anti-microbial drug |
| 05/02/2013 | WO2013059922A1 Limit size lipid nanoparticles and related methods |
| 05/02/2013 | WO2013059898A1 Pharmaceutical compositions containing sesquiterpene lactones belonging to the class of furan heliangolides for the treatment of parasitic infections and tumours |
| 05/02/2013 | WO2013040295A3 Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation |
| 05/02/2013 | WO2013036850A3 Modulation of midbody derivatives |
| 05/02/2013 | WO2013035081A3 Formulation for the controlled release of one or several substances in the digestive tract of a mammal |
| 05/02/2013 | WO2013030679A3 Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
| 05/02/2013 | WO2013020040A3 Radiated cancer cells as a vehicle for cancer nanotherapy |
| 05/02/2013 | WO2013004234A3 Methods for producing liposomes |
| 05/02/2013 | WO2013003827A3 Macrogol 15 hydroxystearate formulations |
| 05/02/2013 | WO2012174262A9 Formulations and methods of treating subjects having central nervous system, endocrine, inflammatory or cardiovascular disorders or at-risk thereof with highly purified omega-3 fatty acid formulations |
| 05/02/2013 | WO2012170334A4 Dressings and related methods therefor |
| 05/02/2013 | WO2012163827A3 Ophthalmic preparation comprising a pgf2alpha analogue |
| 05/02/2013 | WO2012084126A3 Formulation of lacosamide |
| 05/02/2013 | WO2012058545A3 Process for analyzing and establishing dosage size in an ingestible film |
| 05/02/2013 | WO2008024437A3 Sorbic acid analog co-crystals |
| 05/02/2013 | US20130110066 Foam and Delivery System for Treatment of Postpartum Hemorrhage |
| 05/02/2013 | US20130109762 Silk particles for controlled and sustained delivery of compounds |
| 05/02/2013 | US20130109747 Pharmaceutical formulation |
| 05/02/2013 | US20130109719 Method of treating attention deficit disorders with d-threo methylphenidate |
| 05/02/2013 | US20130109700 Topical Itraconazole Formulations and Uses Thereof |
| 05/02/2013 | US20130109637 Methods and formulations for treating sialic acid deficiencies |
| 05/02/2013 | US20130108737 Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
| 05/02/2013 | US20130108711 Methods for treating diseases of the lung |
| 05/02/2013 | US20130108703 Orally Disintegrating Tablet Compositions of Lamotrigine |
| 05/02/2013 | US20130108701 Solid Dosage Forms of Antipsychotics |
| 05/02/2013 | US20130108700 Methods and compositions for wound treatment |
| 05/02/2013 | US20130108699 Highly dispersible granulate for the preparation of formulations of high dosage active substances and procedure for obtaining high dosage active substances thereof |
| 05/02/2013 | US20130108698 Enteric Coated Particles Containing An Active Ingredient |
| 05/02/2013 | US20130108697 Modified release dosage form |
| 05/02/2013 | US20130108696 Coated capsules and tablets of a fatty acid oil mixture |
| 05/02/2013 | US20130108695 Dosage Form |
| 05/02/2013 | US20130108694 Dry blend formulation of tetrahydrobiopterin |
| 05/02/2013 | US20130108693 Dual Controlled Release Dosage Form |
| 05/02/2013 | US20130108692 Compositions and methods for treating influenza |
| 05/02/2013 | US20130108689 Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs |
| 05/02/2013 | US20130108688 Delivery of H2 Antagonists |
| 05/02/2013 | US20130108687 Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders |
| 05/02/2013 | US20130108683 Compositions and methods for treating partial and full thickness wounds and injuries |